மருத்துவ அறிஞர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மருத்துவ அறிஞர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மருத்துவ அறிஞர் Today - Breaking & Trending Today

Study lists five facts to know about antihistamines


Study lists five facts to know about antihistamines
If you are one of the millions of people worldwide suffering from allergies, you may take an antihistamine pill to ward off hives, sneezing and watery eyes.
But you may be taking your medications incorrectly, says Derek Chu, a McMaster University allergy expert and clinical scholar.
People need to rethink what they stock in their home cabinets as allergy medicines, what hospitals keep on formulary, and what policymakers recommend. The message needs to get out. This publication is on time for the spring allergy season and as COVID vaccines roll out, for which rashes are common and antihistamines can be helpful. ....

Gordon Sussman , Derek Chu , Emily Henderson , Mcmaster University , University Of Toronto Temerty Faculty Medicine , Canadian Medical Association Journal , Allergy Expert , Clinical Scholar , Temerty Faculty , கோர்டந் ஸஸ்மந் , டெரெக் சூ , எமிலி ஹென்டர்சன் , மக்மாஸ்டர் பல்கலைக்கழகம் , கனடியன் மருத்துவ சங்கம் இதழ் , ஒவ்வாமை நிபுணர் , மருத்துவ அறிஞர் ,

BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set


Share this article
Share this article
SAN RAFAEL, Calif., Jan. 10, 2021 /PRNewswire/  BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A.  This is the largest global Phase 3 study to date for any gene therapy in any indication, with 134 participants.  All participants in the study received a single dose of valoctocogene roxaparvovec and completed a year or more of follow-up. 
Figure 1: Box-and-Whiskers Plot of Factor VIII Activity in 4-Week Intervals, Subset Population (N=17 ) - Key: The boxes show the interquartile ranges with the lines in the boxes indicating medians. The ends of the whiskers represent the minimum and maximum values and diamonds indicate the means. - Includes only HIV-negative subjects dosed 2 or more years prior to Nov 2020 data cut date. One subjec ....

United States , University Of Southern California , Los Angeles , Hank Fuchs , Md Research Professor Of Pediatrics , Biomarin Pharmaceutical Inc , University Of Michigan , Worldwide Research , Thrombosis Program At Children Hospital Los Angeles , Coagulation Laboratory Laurencea Boxer , Communicable Diseases Department Of Pathology Michigan Medicine , Biomarin Pharmaceutical , Annualized Bleeding Rate , Median Annualized Bleeding Rate , Rollover Population , Coagulation Director , Special Coagulation Laboratory Laurence , Communicable Diseases Department , Pathology Michigan Medicine , Guy Young , Thrombosis Program , Hospital Los Angeles , Clinical Scholar , Keck School , Health Care Amp Hospitals , Clinical Trials Amp Medical Discoveries ,